NGM Bio to Present at Three Upcoming Investor Conferences
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present at three investor conferences. The presentations are scheduled for:
- November 18, 2020: Jefferies Virtual London Healthcare Conference at 12:00 PM ET
- November 18, 2020: Stifel Virtual Healthcare Conference at 2:40 PM ET
- November 23, 2020: 32nd Annual Piper Sandler Virtual Healthcare Conference at 12:00 PM ET
A live webcast will be available on the NGM website, and a replay of the presentation will be archived for 90 days.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at three upcoming investor conferences.
Wednesday, November 18, 2020
Event: Jefferies Virtual London Healthcare Conference
Time: 12:00 pm ET
Wednesday, November 18, 2020
Event: Stifel 2020 Virtual Healthcare Conference
Time: 2:40 pm ET
Monday, November 23, 2020
Event: 32nd Annual Piper Sandler Virtual Healthcare Conference
Time: 12:00 pm ET
A live webcast of these presentations will be available under the Investors and Media section of NGM’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM’s site for 90 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contact: Alex Schwartz ir@ngmbio.com | Media Contact: Liz Melone media@ngmbio.com |
FAQ
What presentations will NGM Biopharmaceuticals provide in November 2020?
What is the schedule for NGM's investor conferences in November 2020?
Where can I watch the NGM Biopharmaceuticals presentations?
How long will the NGM conference replay be available?
